ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

INSTITUTIONAL MARKETING PRACTICES IN THE PHARMACEUTICAL INDUSTRY

Akshat Ashthana*, Devashish Jena
S.N. College of Pharmacy, Lakhauwa, Jaunpur, India
Corresponding Author

ABSTRACT

Institutional marketing in the pharmaceutical industry represents a specialized and strategically significant segment of healthcare product distribution that focuses on supplying medicines and healthcare products directly to institutions such as government hospitals, private hospital chains, defense establishments, railways, public health programs, and non-governmental organizations. Unlike retail pharmaceutical marketing, which primarily targets individual physicians and pharmacies, institutional marketing operates through structured procurement systems, tender-based purchasing, rate contracts, and centralized supply mechanisms. This system plays a critical role in ensuring large-scale drug availability, affordability, and accessibility across public and private healthcare infrastructures.

In India, institutional marketing has gained increasing importance due to the expansion of government-sponsored health schemes, rising hospital infrastructure, and large-scale public procurement programs. Regulatory authorities such as the Central Drugs Standard Control Organization and pricing regulators like the National Pharmaceutical Pricing Authority influence pricing policies, compliance requirements, and quality standards that directly impact institutional sales strategies. Additionally, procurement platforms such as the Government e Marketplace have introduced transparency, digitalization, and competitive bidding mechanisms into the pharmaceutical supply chain.

This case study explores the structural framework, operational mechanisms, marketing strategies, ethical considerations, regulatory environment, and economic implications of institutional marketing practices in the pharmaceutical industry. It examines how pharmaceutical companies participate in open and limited tenders, technical and financial bid submissions, and L1 (lowest bidder) selection systems while maintaining compliance with national drug regulations and ethical marketing guidelines issued by organizations such as the World Health Organization. The study also highlights the differences between retail and institutional marketing in terms of pricing strategy, relationship management, bulk purchasing agreements, distribution logistics, and payment cycles.

Furthermore, the study evaluates key marketing approaches such as key account management, strategic pricing models, portfolio positioning, supply reliability assurance, and post-procurement service support. Ethical challenges including transparency issues, delayed payments, price control regulations, and intense market competition are critically analyzed. The role of policy frameworks such as Drug Price Control Order (DPCO) and Uniform Code for Pharmaceutical Marketing Practices (UCPMP) is also discussed to understand their influence on fair competition and responsible marketing behavior.

The pharmacoeconomic perspective of institutional marketing is assessed by examining cost-effectiveness, generic substitution, bulk procurement advantages, and the impact of competitive bidding on healthcare affordability. Through a systematic analysis of procurement processes and real-world institutional participation models, this case study demonstrates how institutional marketing serves as a backbone of large-scale medicine distribution while balancing profitability, regulatory compliance, and public health objectives.

In conclusion, institutional marketing in the pharmaceutical industry is not merely a sales function but a complex, policy-driven, compliance-oriented, and strategically managed domain that significantly contributes to healthcare delivery systems. The evolving digital procurement ecosystem, increasing regulatory scrutiny, and emphasis on ethical standards are shaping the future of institutional pharmaceutical marketing in India and globally.

INTRODUCTION

The pharmaceutical industry is one of the most dynamic, research-intensive, and highly regulated industries in the world. It plays a crucial role in improving public health by ensuring the availability, safety, efficacy, and affordability of medicines. Marketing in the pharmaceutical sector differs significantly from traditional consumer marketing because medicines are not ordinary consumer goods; they are life-saving and life-sustaining products. Therefore, pharmaceutical marketing must operate within strict ethical, legal, and regulatory frameworks. Among the various segments of pharmaceutical marketing, institutional marketing has emerged as a strategically important and rapidly expanding domain.

Institutional marketing in the pharmaceutical industry refers to the process of promoting, supplying, and distributing pharmaceutical products directly to institutions such as government hospitals, private hospital chains, defense medical

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

services, railway hospitals, public health programs, charitable organizations, and large healthcare networks. Unlike retail marketing, which focuses on doctors, clinics, and pharmacies for prescription generation, institutional marketing is centered around bulk procurement systems, tender participation, rate contracts, centralized purchasing bodies, and long-term supply agreements.

In recent years, digital transformation has significantly reshaped institutional pharmaceutical marketing. The introduction of electronic procurement platforms such as the Government e Marketplace has enhanced transparency, competitiveness, and efficiency in government purchasing processes. Pharmaceutical companies must now comply with structured tender documentation, technical qualification criteria, financial bidding standards, and supply capability assessments. This has increased the complexity of institutional marketing operations and shifted the focus from promotional tactics to compliance-driven strategic management.

international markets. These companies maintain dedicated institutional marketing divisions that focus on government tenders, hospital supply contracts, and international bulk procurement programs. The institutional business often contributes significantly to total revenue, especially for generic drug manufacturers.

Ethical and legal considerations are central to institutional marketing practices. Organizations such as the World Health Organization emphasize transparency, rational drug use, and ethical promotional behavior. In India, marketing practices are guided by policy frameworks that aim to prevent unethical inducements, ensure fair competition, and promote patient welfare. Unlike retail marketing, where medical representatives interact

LITERATURE REVIEW

Literature review is an essential component of any academic case study as it provides a theoretical foundation and establishes the research context by analyzing previously published studies, reports, and regulatory guidelines. In the context of institutional marketing practices in the pharmaceutical industry, literature reveals that this segment has evolved significantly due to regulatory reforms, healthcare expansion, digital procurement systems, and increased emphasis on ethical marketing standards.

Several studies highlight that pharmaceutical marketing differs fundamentally from traditional consumer marketing because the end user (patient) is not the direct decision-maker. Instead, institutional marketing involves multiple stakeholders such as hospital procurement committees, government tender authorities, supply chain managers, pharmacists, and regulatory bodies. According to guidelines issued by the World Health Organization, pharmaceutical promotion and procurement should prioritize rational drug use, transparency, and patient safety. WHO emphasizes that procurement decisions must be based on quality, efficacy, safety, and cost-effectiveness rather than promotional influence.

Recent literature also emphasizes the digital transformation of procurement systems. The implementation of e-procurement platforms such as the Government e Marketplace has increased transparency, reduced corruption risks, and improved competitive fairness in pharmaceutical tendering. Researchers note that digital bidding systems require pharmaceutical companies to strengthen documentation accuracy, financial planning, supply forecasting, and compliance management.

Studies comparing retail and institutional marketing practices demonstrate distinct strategic differences. Retail marketing focuses on physician engagement, brand promotion, and prescription generation, whereas institutional marketing emphasizes relationship management with procurement committees, pricing competitiveness, long-term supply reliability, and logistical efficiency.

In summary, the reviewed literature establishes that institutional marketing practices in the pharmaceutical industry are shaped by regulatory oversight, economic considerations, ethical guidelines, digital transformation, and strategic supply chain management. Previous studies consistently conclude that successful institutional marketing requires integration of compliance, cost management, quality assurance, and long-term relationship building. The evolving healthcare landscape continues to expand the importance of structured institutional marketing systems in ensuring equitable access to medicines.

DRUG PROFILE: CEFTRIAXONE

1. Introduction to the Drug

Ceftriaxone is a third-generation cephalosporin antibiotic widely used in hospital settings for the treatment of moderate to severe bacterial infections. Due to its broad-spectrum antibacterial activity, long half-life, and convenient once-daily dosing, it is one of the most commonly procured injectable antibiotics in institutional healthcare setups.

2. Drug Classification

- **Pharmacological Class:** Third-generation cephalosporin
- **Therapeutic Class:** Broad-spectrum antibiotic
- **Dosage Form:** Injection (IV/IM
- **Strengths:** 250 mg, 500 mg, 1 g, 2 g

3. Mechanism of Action

Ceftriaxone acts by inhibiting bacterial cell wall synthesis.
It binds to penicillin-binding proteins (PBPs), preventing cross-linking of peptidoglycan chains, which leads to bacterial cell lysis and death.
It is bactericidal in action.

4. Pharmacokinetics

- **Absorption:** Administered IV or IM

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

- **Bioavailability:** 100% (parenteral)
- **Protein Binding**: ~85–95%
- **Half-life:** 6–9 hours
- **Excretion:** Renal and biliary

Long half-life makes it suitable for institutional settings because once-daily dosing reduces nursing workload.

5. Indications

- Pneumonia
- Septicemia
- Meningitis
- Urinary tract infection
- Intra-abdominal infections

6. Contraindications

- Hypersensitivity to cephalosporins
- Neonates with hyperbilirubinemia
- Severe beta-lactam allergy

7. Adverse Drug Reactions

- Diarrhea
- Injection site pain
- Allergic reactions

Rare: Biliary sludge formation

CASE PRESENTATION

Institutional Marketing Participation Case

1. Background of the Case

This case study presents the institutional marketing strategy of a mid-sized Indian pharmaceutical company, "XYZ Pharma Pvt. Ltd." (hypothetical name used for academic purposes), participating in a state government hospital tender for the supply of Ceftriaxone Injection 1 g.

2. Tender Notification Details

- **Procuring Authority:** State Medical Services Corporation
- **Contract Duration:** 1 Year
- **Delivery:** District Warehouses

3. Company Profile (XYZ Pharma Pvt. Ltd.)

- Manufacturing Facility: WHO-GMP certified
- Product Portfolio: Antibiotics, analgesics, injectables
- Market Segment: Institutional + Limited Retail

4. Technical Bid Submission

XYZ Pharma submitted:

- Manufacturing license copy
- WHO-GMP certificate
- Product approval documents
- Stability data
- Batch manufacturing records
- Quality control certificates
- Performance certificate from previous supply
- The company successfully qualified in the technical evaluation round.

5. Financial Bid Strategy

The company analyzed:

- Competitor pricing trends
- Raw material cost
- Logistics expenses
- Expected margin

MARKETING STRATEGIES IN INSTITUTIONAL PHARMACEUTICAL SECTOR

Institutional marketing in the pharmaceutical industry requires a fundamentally different strategic approach compared to retail pharmaceutical marketing. While retail marketing focuses on prescription generation through doctors and pharmacies, institutional marketing emphasizes bulk procurement, competitive pricing, compliance management, supply reliability, and long-term contractual relationships. This section analyzes the major marketing strategies adopted by pharmaceutical companies in the institutional sector.

Key Account Management Strategy

One of the most important strategies in institutional marketing is Key Account Management (KAM). In this approach, pharmaceutical companies treat major institutions such as state medical services corporations, government hospitals, defense medical services, railway hospitals, and large private hospital chains as "key accounts."

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

- Track upcoming tenders
- Monitor institutional demand trends
- Ensure compliance documentation is updated

2. Competitive Pricing Strategy

Pricing is the backbone of institutional marketing. Most government tenders operate on the L1 concept (lowest qualified bidder). Therefore, companies adopt strategic pricing models **such as:**

- Cost-plus pricing with minimal margin
- Volume-based pricing
- Long-term contract pricing

Pricing decisions consider:

- Raw material cost
- Manufacturing cost
- Risk of penalty

3. Product Portfolio Strategy

Institutional marketing focuses heavily on essential medicines and high-demand hospital products. Products commonly targeted include:

- Injectable antibiotics (e.g., ceftriaxone)
- IV fluids, Analgesics, Antipyretics
- Anti-hypertensives
- Emergency drugs

4. Regulatory Compliance Strategy

Institutional marketing requires strict regulatory adherence. Companies must ensure:

- Valid manufacturing licenses
- WHO-GMP certification
- Product approvals from the Central Drugs Standard Control Organization

5. After-Sales and Service Support Strategy

Institutional marketing does not end with tender award. Post-supply service is equally **important:**

- Handling product complaints
- Maintaining supply continuity
- Strong service support builds long-term institutional trust.

8. Retail vs Institutional Marketing Comparison

PHARMACOECONOMIC ANALYSIS

Pharmacoeconomics refers to the study of cost and economic impact of pharmaceutical products on healthcare systems. In institutional pharmaceutical marketing, pharmacoeconomic evaluation plays a crucial role because procurement decisions are highly price-sensitive and budget-driven. Government hospitals and large healthcare institutions operate under fixed annual budgets; therefore, cost-effectiveness becomes a primary selection criterion during tender evaluation.

1. Importance of Pharmacoeconomics in Institutional Sector

Institutional procurement focuses on:

- Cost minimization
- Budget optimization
- Bulk procurement through tender systems reduces per-unit cost of medicines compared to retail distribution channels.

2. Cost-Minimization Analysis

In many institutional tenders, drugs with similar therapeutic efficacy are compared primarily on cost. For example, generic ceftriaxone supplied through institutional tenders is significantly cheaper than branded retail versions.

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

Cost Minimization Ensures

- Lower government expenditure
- Efficient use of public funds



Comparative cost analysis between retail and institutional bulk pricing of injectable antibiotics.

3. Cost-Effectiveness Analysis

Cost-effectiveness considers both cost and clinical outcome. Institutional buyers evaluate:

- Therapeutic effectiveness
- Hospital stay reduction
- Drugs included in the Essential Medicines List by the World Health Organization are often prioritized due to proven cost-effectiveness.

4. Impact of Price Regulation

Price regulation under policies implemented by the National Pharmaceutical Pricing Authority ensures that essential medicines remain affordable.

Price Ceilings Influence

- Tender quoting strategy
- Profit margin calculation
- Competitive positioning
- Companies must balance sustainability with affordability.

5. Bulk Procurement Advantage

Bulk purchasing leads to:

- Economies of scale
- Stable revenue forecasting
- This economic advantage makes institutional marketing attractive despite lower margins.

CHALLENGES IN INSTITUTIONAL PHARMACEUTICAL MARKETING

Institutional marketing, despite offering bulk procurement advantages, faces multiple operational, financial, regulatory, and competitive challenges. These challenges directly affect profitability, sustainability, and long-term institutional participation.

- Increased patient access

1. Intense Price Competition

Most institutional tenders follow the L1 (lowest bidder) concept. This leads to:

- Extremely low profit margins
- Aggressive underquoting
- Companies often operate at minimal margins just to maintain market presence.

2. Delayed Payment Cycles

Government institutions frequently delay payments by 90–180 days. This causes:

- Working capital blockage
- Cash flow imbalance
- Small and mid-sized companies face significant financial strain.

3. Strict Regulatory Compliance

Institutional supply requires:

- Continuous GMP compliance
- Regulatory supervision by the Central Drugs Standard Control Organization increases accountability but also operational pressure.

4. Risk of Blacklisting

Failure in supply timelines or quality standards can result in:

- Contract termination
- Financial penalties
- Suspension from future tenders

5. Logistics and Supply Chain Complexity

Bulk supply to multiple district warehouses requires:

- Transport coordination
- Emergency stock management

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

FUTURE TRENDS IN INSTITUTIONAL MARKETING

Despite challenges, institutional pharmaceutical marketing is evolving with modernization and digital reforms.

1. Digital Tendering Expansion

Increased adoption of e-procurement platforms such as the Government e Marketplace ensures:

- Transparency
- Faster evaluation
- Reduced corruption
- Real-time tracking

2. Data-Driven Pricing Strategy

Companies are increasingly using:

- Market analytics
- Competitor price tracking
- Demand forecasting tools
- AI-based tender analysis
- This improves bidding accuracy.

3. Growth of Generic Medicines

Promotion of cost-effective generic drugs increases institutional demand and improves healthcare accessibility.

4. Stronger Compliance Systems

Future institutional marketing will emphasize:

- Digital audit trails
- Quality transparency
- Sustainable pricing
- Ethical accountability

CONCLUSION

Institutional marketing in the pharmaceutical industry represents a highly structured, compliance-driven, and strategically significant segment of healthcare distribution. Unlike retail pharmaceutical marketing, which primarily focuses on prescription generation and brand promotion, institutional marketing operates through bulk procurement systems, tender-based selection processes, long-term contractual agreements, and regulatory supervision. This case study has comprehensively examined the operational framework, marketing strategies, regulatory requirements, pharmacoeconomic considerations, and future outlook of institutional pharmaceutical marketing.

This study also emphasized the importance of regulatory and ethical considerations in institutional marketing. Compliance with national drug regulations, adherence to quality standards, and transparency in procurement are critical for sustainable participation. Institutions rely heavily on regulatory oversight and price control mechanisms to safeguard public healthcare interests. Ethical conduct, therefore, becomes not only a legal requirement but also a strategic advantage that enhances corporate credibility and long-term institutional relationships.

Through SWOT analysis and case presentation, it is evident that institutional marketing offers both opportunities and challenges. While it ensures bulk orders, reduced promotional expenses, and stable contracts, it also involves low profit margins, delayed payment cycles, and high compliance burdens. Companies that adopt strong key account management systems, efficient logistics planning, competitive pricing models, and robust documentation practices are better positioned for success in this sector.

The future of institutional pharmaceutical marketing appears increasingly digital and data-driven. Expansion of e-procurement systems, greater transparency, analytics-based pricing decisions, and stronger regulatory audits are reshaping the institutional landscape. Digital tendering platforms and improved governance mechanisms are expected to reduce corruption risks and enhance accountability. At the same time, growing public healthcare investment and demand for cost-effective generic medicines will continue to expand institutional market opportunities.

In conclusion, institutional pharmaceutical marketing plays a vital role in strengthening healthcare delivery systems by ensuring large-scale availability of essential medicines at affordable prices. It represents a strategic balance between public health responsibility and commercial sustainability. Pharmaceutical companies that integrate regulatory compliance, ethical standards, economic evaluation, and efficient supply chain management into their institutional strategy will achieve long-term growth and credibility.

REFERENCES

(APA 7th Edition Format)

1. *World Health Organization. (2023). WHO model list of essential medicines (23rd ed.). Geneva: WHO Press.*
2. *World Health Organization. (2017). Guidelines on good procurement practices for pharmaceutical products. Geneva: WHO.*
3. *Central Drugs Standard Control Organization. (2022). Drugs and Cosmetics Act and Rules. Ministry of Health and Family Welfare, Government of India.*
4. *National Pharmaceutical Pricing Authority. (2023). Drug Price Control Order (DPCO), 2013 and amendments. Government of India.*
5. *Government of India. (2023). Government e-Marketplace (GeM) procurement manual. Ministry of Commerce and Industry.*
6. *Indian Pharmaceutical Alliance. (2022). Indian pharmaceutical industry annual report.*
7. *Kotler, P., & Keller, K. L. (2022). Marketing management (16th ed.). Pearson Education.*
8. *Rang, H. P., Dale, M. M., Ritter, J. M., & Flower, R. J. (2020). Rang & Dale's pharmacology (9th ed.). Elsevier.*
9. *Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2022). Goodman & Gilman's the pharmacological basis of therapeutics (14th ed.). McGraw-Hill Education.*
10. *Tripathi, K. D. (2023). Essentials of medical pharmacology (9th ed.). Jaypee Brothers Medical Publishers.*
11. *Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G., & Torrance, G. W. (2015). Methods for the economic*

ISSN (Online): 2455-3662
EPRA International Journal of Multidisciplinary Research (IJMR) - Peer Reviewed Journal
Volume: 12| Issue: 4| April 2026|| Journal DOI: 10.36713/epra2013 || SJIF Impact Factor 2026: 8.753 || ISI Value: 1.188

evaluation of health care programmes (4th ed.). Oxford University Press.

12. *Phillips, K. A., Sanders, G. D., Siegel, J. E., et al. (2016). Recommendations for good practice in cost-effectiveness analysis. Journal of the American Medical Association, 316(10), 1093–1103.*
13. *OECD. (2021). Pharmaceutical procurement and reimbursement policies. Organisation for Economic Co-operation and Development.*
14. *Ministry of Health and Family Welfare. (2022). National Health Policy of India. Government of India.*
15. *Government of India. (2022). Public procurement policy guidelines. Ministry of Finance.*
16. *IMS Health (IQVIA). (2023). Indian pharmaceutical market analysis report.*
17. *Kaplan, R. S., & Norton, D. P. (2008). Strategy-focused organization. Harvard Business School Press.*
18. *Porter, M. E. (2008). The five competitive forces that shape strategy. Harvard Business Review, 86(1), 78–93.*
19. *Transparency International. (2021). Corruption risks in pharmaceutical procurement.*
20. *World Bank. (2020). Improving transparency in public pharmaceutical procurement systems.*
21. *European Commission. (2019). Public procurement guidance for pharmaceuticals.*
22. *Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States. Journal of the American Medical Association, 316(8), 858–871.*
23. *Quick, J. D., Hogerzeil, H. V., et al. (2012). Twenty-five years of essential medicines. The Lancet, 380(9859), 225–227.*
24. *Mossialos, E., Mrazek, M., & Walley, T. (2004). Regulating pharmaceuticals in Europe. Open University Press.*
25. *United Nations Development Programme. (2021). Access to medicines and procurement reform report.*